Mitapivat sulfate - Generic Drug Details

What are the generic sources for mitapivat sulfate and what is the scope of freedom to operate?

Mitapivat sulfate is the generic ingredient in two branded drugs marketed by Agios Pharms Inc and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mitapivat sulfate has one hundred and ninety-one patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for mitapivat sulfate

International Patents:	191
US Patents:	9
Tradenames:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	14
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mitapivat sulfate
DailyMed Link:	mitapivat sulfate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mitapivat sulfate

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for mitapivat sulfate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	PHASE2
Agios Pharmaceuticals, Inc.	PHASE2
EuroBloodNet Association	Phase 2

See all mitapivat sulfate clinical trials

Pharmacology for mitapivat sulfate

Drug Class	Pyruvate Kinase Activator
Mechanism of Action	Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A Inducers P-Glycoprotein Inhibitors Pyruvate Kinase Activators UGT1A1 Inducers

Anatomical Therapeutic Chemical (ATC) Classes for mitapivat sulfate

B06AX	Other hematological agents
B06A	OTHER HEMATOLOGICAL AGENTS
B06	OTHER HEMATOLOGICAL AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for MITAPIVAT SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PYRUKYND	Tablets	mitapivat sulfate	5 mg, 20 mg and 50 mg	216196	1	2026-02-17

US Patents and Regulatory Information for mitapivat sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No			Y	Y
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No

International Patents for mitapivat sulfate

Country	Patent Number	Title	Estimated Expiration
Australia	2012250688
Australia	2017221860
Australia	2020200700
Brazil	112013028422
Canada	2834602
Canada	3088328

Supplementary Protection Certificates for mitapivat sulfate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2448582	23C1017	France		PRODUCT NAME: MITAPIVAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE MITAPIVAT, EN PARTICULIER SULFATE DE MITAPIVAT.; REGISTRATION NO/DATE: EU/1/22/1662 20221110
2448582	C202330019	Spain		PRODUCT NAME: MITAPIVAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR SULFATO DE MITAPIVAT; NATIONAL AUTHORISATION NUMBER: EU/1/22/1662; DATE OF AUTHORISATION: 20221109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1662; DATE OF FIRST AUTHORISATION IN EEA: 20221109
2448582	PA2023513,C2448582	Lithuania		PRODUCT NAME: MITAPIVATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC MITAPIVATO SULFATAS; REGISTRATION NO/DATE: EU/1/22/1662 20221109
2448582	122023000025	Germany		PRODUCT NAME: MITAPIVAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE MITAPIVATSULFAT; REGISTRATION NO/DATE: EU/1/22/1662 20221109
2448582	LUC00306	Luxembourg		PRODUCT NAME: MITAPIVAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MITAPIVAT SULFATE; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110
2448582	19/2023	Austria		PRODUCT NAME: MITAPIVAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MITAPIVAT-SULFAT; REGISTRATION NO/DATE: EU/1/22/1662 (MITTEILUNG) 20221110

Mitapivat Sulfate Market Dynamics and Financial Trajectory: Revenue, Exclusivity Timelines, Competitive Risk, and Patent-Linked Pricing Power

Last updated: July 16, 2026

Mitapivat sulfate is commercially tied to the US FDA approval path and to the durability of the active-ingredient and dosage-form/IP estate that controls generic entry and price erosion. The market trajectory is driven by payer uptake in the eligible hemolytic anemia segment (and the specific approved indication), contract pricing dynamics, and the timing of exclusivity and any Paragraph IV posture. Financial performance is most sensitive to (1) formulary access and utilization growth, (2) competitive substitution risk once exclusivity falls, and (3) whether payers treat the therapy as a long-duration chronic spend versus a defined-course product.

Mitapivat sulfate market outlook: what drives demand and pricing power?

Mitapivat sulfate demand is a function of approved indication breadth, patient identification mechanics, and how payers map it to existing standard-of-care comparators. The strongest commercial levers typically are evidence strength in clinical endpoints relevant to payers (transfusion reduction, hemolysis markers, hospitalization outcomes) and ease of administration, which affects adherence and persistence.

What payer segments typically determine mitapivat sulfate utilization

Commercial uptake in specialty hematology products generally concentrates in:

• Large employer and national managed care formularies with hematology specialty committees.
• Pharmacy benefit managers that steer to preferred specialty pharmacies and set step edits.
• Specialty distributors and contract frameworks that determine net price via rebates.

Pricing power: what usually protects net price in hemolytic anemia drugs

For therapies positioned as chronic management, pricing power tends to hold when:

• Switching to alternatives is clinically constrained.
• Real-world persistence is high.
• The payer landscape views the therapy as cost-offsetting (fewer transfusions, fewer acute events).
• The product retains exclusivity long enough that discounting remains incremental rather than competitive.

What market adoption friction can cap revenue growth

Revenue ceilings for new specialty launches often come from:

• Slow diagnostic capture and center-of-excellence referral patterns.
• Prior authorization burden and documentation requirements.
• Budget impact constraints in mid-tier plans.
• Limited reimbursement clarity during early NDC ramp.

When does mitapivat sulfate lose exclusivity and how does that affect revenue decline?

Revenue decline risk correlates with the date when the active ingredient and key formulation or method-of-use IP layers exit exclusivity and when FDA regulatory exclusivities end for the specific NDA/BLA reference.

Exclusivity timing: how revenue compression typically begins

For small-molecule new entrants, revenue compression usually starts in advance of hard expiration through:

• Contract renegotiations tied to “known generic risk.”
• Early launch of competitors under a 180-day exclusivity framework (if applicable).
• Heightened PA criteria and step edits by payers after launch uncertainty resolves.

Generic entry risk: what investors model for mitapivat sulfate

Markets typically model three scenarios:

1. “No generic launch” scenario: patents withstand challenges and exclusivity holds.
2. “Delayed generic” scenario: one or more Paragraph IV suits succeed or result in early resolution, but entry is staggered.
3. “Rapid erosion” scenario: multiple IP barriers fall and a first filer or follow-on generics launch quickly, driving steep net price decline.

How many patents protect mitapivat sulfate and what is the likely challenge profile?

A drug’s financial trajectory depends on whether it has a dense patent estate spanning:

• Composition of matter (active ingredient).
• Crystalline forms/polymorphs (salt forms, hydrates).
• Formulation (granules, tablets, stability).
• Methods of use (specific dosing regimens, patient subsets, endpoint-guided therapy).
• Manufacturing methods and process robustness.

Typical IP layers investors map for small-molecule sulfate salts

For a “sulfate” drug substance, investors commonly focus on:

• Salt-specific claims (mitapivat sulfate composition).
• Solid-state form claims tied to stability and bioavailability.
• Drug product claims that control excipient systems and release profiles.

Patent challenge posture: what Paragraph IV filings mean commercially

If a generic sponsor files an ANDA with Paragraph IV certifications, market expectations shift based on:

• Whether the first-filer gets 180-day exclusivity.
• Timing of district court rulings (injunction likelihood).
• Settlement terms that can include “launch date carve-outs” or supply agreements.

What is the Orange Book status of mitapivat sulfate and what NDCs matter?

Orange Book status is the direct map from listed patents and exclusivities to generic entry timing. The commercial impact is NDC-specific because:

• Formulations can have different expiration dates.
• Additional listed patents can extend blocking effects even after core patents expire.
• Smaller dosage strengths can have separate listings that affect generic launch feasibility.

What to check for revenue risk triggers

The revenue trigger set is:

• Active ingredient and formulation patent expirations tied to the marketed dosage forms.
• Whether listed patents include method-of-use claims that can block “carve-out” substitution.
• Whether any patents are set for near-term expiration relative to the product’s sales growth stage.

What generic entry risks exist for mitapivat sulfate?

Generic entry risk hinges on enforceable IP and on how tightly the approved label binds to patented claims.

How generics typically pressure net price

Once a generic is cleared to market:

• PBMs push for formulary switching and require preferred status.
• Competitors can blend discounting with contracting tactics that reduce net price quickly.
• Patients may remain on therapy if prescribers resist switching, but payer incentives often dominate for chronic therapies.

What could reduce generic substitution speed

Substitution can be slowed if:

• The product is tightly linked to efficacy in specific patient subgroups.
• The label includes dosing titration or monitoring steps that are hard to replicate.
• The generic’s bioequivalence pathway is constrained by formulation attributes.

How does mitapivat sulfate compare with other hemolytic anemia therapies on market dynamics?

Market dynamics compare on 3 axes: payer acceptance, administration burden, and clinical differentiation that drives preference.

Comparative adoption drivers

Typical differentiators that win share:

• Measurable transfusion reduction or biomarker improvements.
• Lower acute-care usage versus alternatives.
• Clear clinical positioning that fits payer criteria and care pathways.

Financial competition pattern: share shift mechanics

In specialty hematology, share shifts can be:

• Direct replacement if clinical endpoints are comparable.
• “Add-on” positioning if the therapy is used in defined refractory settings.
• Geographic or plan-specific preferences based on contracting.

What patent litigation affects mitapivat sulfate and how do settlements change outcomes?

Patent litigation outcome dictates the timing of generic/authorized generic entry and hence the shape of the sales curve.

What to look for in litigation that changes revenue

Revenue-sensitive events include:

• Court rulings that narrow blocking patents.
• Stays that preserve exclusivity until a later date.
• Consent judgments tied to settlement launch dates.

How settlements translate into market effects

Settlement agreements generally produce:

• Earlier generic entry for specified challengers at a defined date.
• Delayed entry for other filers if not covered by the settlement.
• “Authorized generic” risk if the brand authorizes its own competitive channel.

What FDA status and regulatory pathway governs mitapivat sulfate exclusivity?

Regulatory pathway affects exclusivity types and durations (regulatory exclusivity versus patent exclusivity). The product’s approval letter and FDA database entries define:

• Application type (NDA vs supplemental NDA).
• Orphan drug designation, if any.
• Pediatric exclusivity add-ons, if any.
• Reference to any exclusivity-protected clinical trial(s).

FDA exclusivity levers that influence revenue durability

Key financial levers are:

• New chemical entity (NCE) exclusivity (if applicable).
• Orphan drug exclusivity (if designated).
• 3-year new clinical investigation and 5-year changes for supplemental applications (if applicable).

What commercialization metrics define mitapivat sulfate’s financial trajectory?

The near-to-midterm trajectory is determined by sales growth vs net price erosion, with adherence and persistence shaping longer-horizon revenue.

KPIs that correlate with specialty drug financial outcomes

• New patient starts per quarter and site-of-care expansion.
• Persistence at 3, 6, and 12 months (discontinuation rate).
• Net-to-gross ratio trend driven by rebates and contracting.
• Prior authorization approval rate and median time-to-therapy start.
• Utilization in top plans and shift into preferred tiers.

How contract dynamics usually show up in financials

• If net price declines faster than gross price, rebate pressure is rising.
• If utilization grows but revenue lags, it indicates tighter payer terms.
• If both utilization and net price fall, competition risk is real and expanding.

Financial trajectory benchmarks: how fast do specialty drugs like mitapivat sulfate typically scale?

For early-stage specialty launches, revenue growth usually follows an S-curve:

• Initial ramp driven by center-of-excellence prescribing and limited patient identification.
• Mid-phase growth as formulary inclusion expands and PA workflows smooth out.
• Late-phase plateau if payer barriers tighten or if competitive narratives emerge.

What investors watch for quarter-to-quarter inflection

• Acceleration in new starts without net price deterioration.
• Stable or improving persistence supporting longer-duration therapy revenue.
• Downward pressure on net price that correlates with new payer policies.

Which companies could threaten mitapivat sulfate’s market and what are the competitive scenarios?

Competitive threats typically come from:

• Licensed oral therapies targeting similar pathways.
• Emerging generics or authorized generics once IP barriers fall.
• Next-generation drugs with superior safety or convenience profiles.

Scenario matrix: market share and pricing impact

Scenario	Trigger	Expected net price effect	Expected volume effect
Bear	Material IP loss or early settlement; generic/authorized generic credible	Sharp decline	Flat to down
Base	Exclusivity holds; contracting normalizes; PA friction eases gradually	Mild decline	Steady up
Bull	Strong payer pull-through; reduced PA barriers; no credible generic entry window	Stable	Up with margin protection

What formulations are protected by mitapivat sulfate patents and how does that block substitution?

Patent coverage across dosage strengths and drug product attributes can block “functional equivalence” substitutions even if the active ingredient patent expires.

Tablet/capsule/solid-state coverage categories investors map

• Release profile claims (immediate vs modified release).
• Excipient composition claims (binder, disintegrant, coatings).
• Stability and shelf-life claims tied to storage conditions.

Why dosage strength matters in launch timing

Generic sponsors may choose:

• Launch on certain strengths first if patent coverage differs.
• Avoid strengths that require additional stability or manufacturing steps protected by IP.

Key Takeaways

• Mitapivat sulfate’s financial trajectory is primarily an exclusivity and payer-uptake story: net price durability and patient starts determine whether revenue scales or compresses.
• Revenue decline risk accelerates when Orange Book-listed patents and regulatory exclusivity fall, especially if Paragraph IV litigation produces an earlier-than-expected launch window.
• Patent estate density across salt form, solid state, formulation, and method-of-use claims drives generic substitution speed and therefore the shape of future sales.
• The near-term commercialization path is controlled by payer coverage mechanics (PA, formulary position, rebates) and persistence for chronic treatment.

FAQs

1. What are the revenue drivers for mitapivat sulfate in the first 12 months post-launch?
2. How do Paragraph IV filings against mitapivat sulfate affect authorized generic risk and net price?
3. Which Orange Book-listed patent categories most often block generic substitution for small-molecule sulfate salts?
4. Does mitapivat sulfate face an orphan drug exclusivity termination scenario, and how would that change generic timing?
5. What contracting patterns typically increase net-to-gross pressure for specialty hemolytic anemia drugs?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). https://www.accessdata.fda.gov/scripts/cder/daf/